Larimar Therapeutics, Inc. 8K

Larimar Therapeutics reported Q2 2026 results, advanced a rolling BLA and Phase 3 plans for nomlabofusp in Friedreich’s ataxia, and confirmed sufficient cash to fund operations into Q3 2027.

On August 4, 2026, Larimar Therapeutics, Inc. reported its second quarter 2026 financial results and provided a business update highlighting positive longer-term open label data for its lead Friedreich’s ataxia candidate nomlabofusp, including sustained safety, biomarker (skin frataxin) increases, and directional clinical improvements, noted continued patient enrollment and enthusiasm in the ongoing open label study, confirmed FDA alignment from a successful Type B pre-BLA meeting enabling a rolling BLA submission seeking accelerated approval (with the first module already submitted and completion expected in the second half of 2026), reiterated plans to begin dosing patients in a global confirmatory Phase 3 trial in Q3 2026 and target a potential mid-2027 commercial launch, and disclosed a $32.8 million quarterly net loss alongside $156.3 million in cash, cash equivalents and marketable securities supporting an expected cash runway into Q3 2027.

Filing Facts

CIK

1374690

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-331516

Alert Tier

7